Introduction
Hodgkin lymphoma (HL) has become a curable disease after the introduction of improved radiation techniques and combination chemotherapy such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). [1] [2] [3] However, approximately 20-40% of patients with advanced HL who enter a complete remission (CR) with initial chemotherapy will relapse, and 8-18% of patients with advanced HL did not undergo a CR after initial treatment with ABVD. 2, 3 It is unlikely that HL patients who never achieve a CR or relapse within 1 year attain a lasting response to a standard treatment approach, thus they should be offered a novel treatment strategy that may improve their prognosis.
The use of therapeutic monoclonal antibody (mAb) for the treatment of cancer has become a promising approach over the last few years, as exemplified by the great success of mAb against HER2, trastuzumab, used for the treatment of metastatic breast cancer that overexpresses HER2; 4 mAb against CD20, rituximab, used for diffuse large B-cell lymphoma; 5 mAb against vascular endothelial growth factor, bevacizumab, used for metastatic colorectal cancer; 6 and mAb against epidermal growth factor receptor, cetuximab, used for locoregionally advanced squamous-cell carcinoma of the head and neck. 7 Thus, development of promising mAb against refractory HL should also be expected.
We have recently developed a novel chimeric mAb, KM2760, that binds specifically to CC chemokine receptor 4 (CCR4) and whose Fc region is defucosylated to enhance antibody-dependent cellular cytotoxicity (ADCC) by increasing its binding affinity to the Fcg receptor on effector cells. [8] [9] [10] [11] Most importantly, based on the promising results in our previous work, [8] [9] [10] [12] [13] [14] [15] we are currently conducting a phase I clinical trial of anti-CCR4 mAb in patients with CCR4-positive T-cell lymphomas (ClinicalTrials.gov Identifier: NCT00355472). We here extend our earlier KM2760 study on CCR4-positive T-cell neoplasms to classical HL in order to develop a novel treatment strategy for patients with refractory HL.
Materials and methods

Chimeric mAb
The chimeric anti-CCR4 mAb was described previously. 8, 9 Rituximab, which is an isotype-matched mAb with KM2760, was kindly provided by Chugai Pharmaceutical Co. Ltd (Tokyo, Japan).
HL cell lines
The HL cell lines, HDLM-2, 16 L-428, 17 KM-H2, 18 L-540 19 and L-1236 20 were described previously. 14 
Flow cytometry analysis
Expressions of CCR4 on HL cell lines were examined using fluorescein isothiocyanate (FITC)-conjugated mouse anti-CCR4 mAb, KM2160, as described previously. 
Immunohistochemistry
The immunostaining analysis for CCR4 was performed using formalin-fixed, paraffin-embedded sections as described previously. 12, 13, 15 We immunostained for CCR4 in affected lymph nodes of 42 patients with classical HL. The patients gave informed written consent before the sampling procedure, and informed consent was provided according to the Declaration of Helsinki Principle. All cases were diagnosed as classical HL according to the criteria of WHO classification of malignant lymphoma after precise immunohistochemical evaluation. 21 We defined a specimen as being positive for CCR4 if more than 10% of Hodgkin cells or Reed-Sternberg cells were stained with mouse anti-CCR4 mAb, KM2160.
Animals
Male C. B-17/Icr-scid Jcl mice were purchased from CLEA Japan Inc. (Tokyo, Japan) and used at 6-9 weeks of age. All of the in vivo experiments were performed in conformity with United Kingdom Co-ordinating Committee on Cancer Research Guidelines for the Welfare of Animals in Experimental Neoplasia (second edition).
HL tumor-bearing mouse model
L-428 cells (1.5 Â 10 7 ) suspended in 0.2 ml Rosewell Park Memorial Institute (RPMI)-1640 medium with 50% matrigel (BD Matrigel Matrix, BD Biosciences, Bedford, MA, USA) were subcutaneously (s.c.) inoculated into 16 severe combined immunodeficient (SCID) mice, and 50 ml rabbit anti-asialo-GM1 (Wako Pure Chemical Industries Ltd, Osaka, Japan) given intraperitoneally 1 day before tumor inoculation. The tumorbearing mice were divided into two groups of eight mice each for KM2760 or control (saline) injections, respectively, so that the mean tumor volumes might become equal in each group. KM2760 (20 mg/kg) or control injections into the tail veins of the mice were started 18 days after tumor inoculations, when the tumor volume had reached 372-835 (mean 615) mm 3 , and continued weekly for 4 weeks. Tumor volume was calculated by the following formula: tumor volume (mm
Plasma human thymus and activation-regulated chemokine (TARC/CCL17) measurement
The concentrations of human TARC/CCL17, which is the ligand of CCR4, in mouse plasma were measured by enzyme-linked immunosorbent assay using the Human TARC/CCL17 Immunoassay Kit (R&D Systems Inc., Minneapolis, MN, USA) according to the manufacturer's instructions.
Human and mouse effector cells used for ADCC or antibody-dependent cellular phagocytosis (ADCP) assays
Human peripheral blood mononuclear cells (PBMCs) were obtained from healthy adult individuals as described previously. 9 The volunteers gave informed written consent before the sampling procedure, and the informed consent was provided according to the Declaration of Helsinki Principle. Human monocytes/macrophages were prepared from PBMC by magnetic cell sorting using anti-CD3, anti-CD19 and anti-CD56 microbeads and the autoMACS separation unit (Miltenyi Biotech, Bergisch Gladbach, Germany), according to the manufacturer's instructions. The remaining CD3, CD19 and CD56 triple-negative cells consisted of more than 70% monocytes/macrophages, as confirmed by flow cytometry analysis. Mouse mononuclear cells were prepared from naive SCID mouse spleen cells by density centrifugation using lympholyte-M (Cedarlane Laboratories Limited, Hornby, Ontario, Canada) according to the manufacturer's instructions. Mouse monocytes/macrophages were prepared from peritoneal exudate cells of naive SCID mice. These cells were allowed to adhere to a 10 cm plastic culture dish for 2 h in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS). Non-adherent cells were washed out, and the adherent cells were treated with 0.2 mM ethylenediaminetetraacetic acid (EDTA)/phosphate-buffered saline (PBS) and recovered using a cell scraper. These cells consisted of more than 90% monocytes/macrophages, as confirmed by flow cytometry analysis.
ADCC assay
Standard 4-h 51 Cr release assays were performed as described previously using human PBMC or mouse spleen mononuclear cells as effector cells. 
Complement-dependent cytotoxicity assay
Complement-dependent cytotoxicity (CDC) assay were performed using pooled human serum as complement source, as described previously. 9 
Cell proliferation assay
Cell proliferation assays of L-428 exposed to various concentrations of KM2760 were performed using CEllTiter 96 AQueouse One solution Cell Proliferation Assay Kit (Promega Corporation, Madison, WI, USA) as described previously. 9 
ADCP assay
ADCP assays were performed according to the previous report with some modifications. 22 L-428 cells (1.5 Â 10 6 ) were labeled with 3.2 ml of the lipophilic fluorochromes PKH26 (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer's instruction. As L-428 does not express CD20, rituximab was used as control mAb for KM2760. The PKH26-labeled L-428 cells (1 Â 10 4 ) and mouse monocytes/ macrophages (5 Â 10 4 ) were co-cultured with or without KM2760 or rituximab at the final concentration of 10 mg/ml in polypropylene tubes at 371C, 5% CO 2 . After incubation for 1 h, the cells were harvested with 0.2 mM EDTA/PBS supplemented with 10% FBS. After blocking surface Fc receptors with rat serum (DAKO, Kyoto, Japan), the harvested cells were stained with FITC-conjugated anti-F4/80 mAb (Serotec Ltd, Oxford, UK), which specifically binds mouse monocytes/macrophages, at 41C, for 30 min. After washing once, the cells were resuspended in PBS, and analyzed by FACScalibur. PKH26 was detected in the FL2 channel and FITC was detected in the FL1 channel, thus dual-positive cells for FL1 and FL2 represented the L-428 cells phagocytozed by mouse monocytes/macrophages. ADCP assays mediated by human monocytes/macrophages were also examined in the same manner. Human monocytes/ macrophages were stained with FITC-conjugated anti-CD14 mAb (BD Biosciences, San Diego, CA, USA).
The spontaneous phagocytosis by mouse or human monocytes/macrophages was calculated from the cultures without KM2760/rituximab in the same manner. The mixture of the PKH26-labeled L-428 cells (1 Â 10 4 ) and mouse monocytes/ macrophages (5 Â 10 4 ) was stained with FITC-conjugated anti-F4/80 mAb without pre-incubation, and used as control. The mixture of the PKH26-labeled L-428 cells (1 Â 10 4 ) and human monocytes/macrophages (5 Â 10 4 ) was also stained with FITCconjugated anti-CD14 mAb without pre-incubation, and used as control. The percent phagocytosis is expressed as mean7s.d. of three independent experiments.
Statistical analysis
The differences in the tumor volume and plasma TARC/CCL17 concentration between control and KM2760-treated groups were examined with the Mann-Whitney U-test. The significance of the difference between percent spontaneous and rituximab or KM2760-dependent phagocytosis of L-428 cells was assessed by the Mann-Whitney U-test. The correlations between tumor volume and plasma TARC/CCL17 concentration were examined using the Spearman rank-correlation coefficient. Data were analyzed with the aid of StatView software (SAS Institute, version 5.0, Cary, NC, USA). In this study, Po0.05 was considered significant. Cr release assay in the presence of effector PBMC obtained from three healthy individuals and KM2760 at the concentrations indicated on the x axis. The E/T ratio was fixed at 50:1. All experiments were performed in triplicate, and the percent cell lysis is presented as the mean7s.d. 
Results
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Expression of CCR4 on Hodgkin's cells or ReedSternberg cells obtained from patients with classical HL
Ten of 42 cases (23.8%). were positive for CCR4. An immunohistochemical image of an affected lymph node from a CCR4-positive HL patient is shown in Figure 2 . The Reed-Sternberg cell shows membrane staining for CCR4, and reactive nontumor lymphocytes surrounding the HL tumor cells express CCR4. The latter observation is consistent with reports by us 14 and by van den Berg et al.
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KM2760-induced potent anti-tumor activity in the HL tumor-bearing mouse model in the therapeutic setting
In the therapeutic setting with s.c. inoculation models, injection of KM2760 showed therapeutic efficacy, as demonstrated by the effect on the tumor volume and plasma human TARC/CCL17 concentration. The tumor volumes of KM2760 recipients and control mice at day 35 after tumor inoculation were 3297238 and 19437846 mm 3 , respectively. This difference was statistically significant (P ¼ 0.0046) (Figure 3a and b) . The plasma TARC/CCL17 concentrations of KM2760 recipients and control mice at day 35 after tumor inoculation were 237373244 and 21 886711 179 pg/ml, respectively. This difference was statistically significant (P ¼ 0.0087) (Figure 3c ). There was a significant correlation between the tumor volumes and plasma human TARC/CCL17 concentrations in the mice (coefficient ¼ 0.974, P ¼ 0.0002) (Figure 3d) . None of the mice in this study showed toxicity that could be caused by KM2760 injections. Cr release assay (data not shown).
Control
Analysis of CDC and anti-proliferation activity mediated by KM2760
KM2760 did not exhibit any CDC mediated by human complement or direct anti-proliferation activity against L-428 cells (data not shown). 
KM2760-enhanced phagocytosis mediated by monocytes/macrophages
The percent spontaneous phagocytosis of L-428 cells mediated by mouse monocytes/macrophages during 1 h incubation was 36.171.6%. Rituximab-and KM2760-induced phagocytosis was 36.772.7 and 45.974.5%, respectively. The latter was significantly greater than either the spontaneous or rituximabinduced phagocytosis (P ¼ 0.0495, P ¼ 0.0495, respectively) ( Figure 4a ). Spontaneous phagocytosis of L-428 cells mediated by human monocytes/macrophages was 36.771.0% compared with 34.072.5 and 42.772.1% with rituximab and KM2760, respectively. The latter was also significantly greater than spontaneous or rituximab-induced phagocytosis (P ¼ 0.0495, P ¼ 0.0495, respectively) ( Figure 4b ). Calculation of the percent phagocytoses of L-428 cells is shown in Figure 4c . These results indicate that KM2760 significantly enhanced the phagocytic activity mediated by either mouse or human monocytes/ macrophages.
Discussion
This study showed that not only some HL cell lines but also tumor cells from certain HL patients express CCR4. To our knowledge, no other investigators, including Vermeer et al., 24 have previously reported the expression of CCR4 by HL tumor cells from patients ex vivo. On the other hand, some groups have already reported that certain HL cell lines do express CCR4, 23, 25 as confirmed in this study. As most HL cell lines have been derived from patients with advanced or chemotherapy refractory disease and from extralymph node sites such as pleural effusions, [16] [17] [18] [19] [20] we surmise that HL cells from some patients with advanced or chemotherapy refractory disease, and with extralymph node lesion may indeed express CCR4. The clinical significance of CCR4 expression in HL tumor cells needs to be further explored.
KM2760 induced robust ADCC activity against CCR4-positive HL cell lines in a dose-dependent manner in the presence of any PBMC obtained from three healthy individuals. KM2760 also induced potent antitumor activity in an HL tumor-bearing mouse model. HL cells express high levels of TARC/CCL17, 21, 23 and an elevated serum level of TARC/CCL17 was observed in patients with HL. 26 Because we have previously reported that L-428 produced TARC/CCL17, 14 we were able to use plasma human TARC/CCL17 concentrations as a surrogate tumor marker in the L-428-bearing mouse model. As shown in this study, plasma human TARC/CCL17 concentrations in the mice corresponded well to tumor volumes. To clarify the mechanism of KM2760-induced potent anti-HL activity in the mouse model, we analyzed KM2760-induced CDC and anti-proliferation activity against L-428 in vitro. As KM2760 did not exhibit any CDC or direct antiproliferation activity, the KM2760-induced potent antitumor activity in the mouse model must have been exerted through ADCC mediated by mouse effector cells. We evaluated the effector function of mouse spleen mononuclear cells using a standard 4-h 51 Cr release assay and found that mouse mononuclear cells did not mediate any KM2760-induced ADCC against L-428 cells. As ADCC measured by the standard 51 Cr release assay using mononuclear cells is mostly mediated by NK cells, 27 the above finding indicated that mouse NK cells did not mediate KM2760-induced ADCC. Recently, Uchida et al. 28 have reported that mouse anti-mouse CD20 mAb exerted its in vivo B-cell-depleting activity via monocytes/macrophages. Therefore, we next evaluated whether mouse monocytes/ macrophages could mediate KM2760-induced ADCC. Because it has been reported that the 51 Cr release assay could not correctly measure ADCC mediated by monocytes/macrophages, 29 we adopted the ADCP assay. KM2760 significantly enhanced phagocytosis mediated by mouse monocytes/macrophages in this study. Collectively, these results indicated that the potent antitumor activity of KM2760 in the mouse model was mainly mediated by monocytes/macrophages. Thus, in mice, despite the inability of NK cells to mediate ADCC, KM2760 induced potent antitumor activity mediated by monocytes/ macrophages. With respect to the human system, KM2760 also enhanced phagocytosis by monocytes/macrophages. Moreover, it induced robust ADCC mediated by NK cells in this study. Therefore, it is conceivable that KM2760 would have much more potent antitumor activity in humans than in mice.
Recently, we have reported how the abundant non-tumor cells in the environment of a small number of HL tumor cells contribute to the immunopathogenesis. Thus, the CD4 þ
CD25
þ CCR4 þ regulatory T (Treg) cells migrate to the HL cells in a process mediated by the chemokines TARC/CCL17 and/or MDC/CCL22 -which are produced by the HL cells -and are capable of suppressing the host's antitumor response. 14 We have also reported that KM2760 can deplete the CCR4 þ T cells and inhibit the migration of CD4 þ CD25 þ T cells induced by the HL cells.
14 In this study, we have demonstrated a promising antitumor activity of KM2760 against CCR4-positive HL. Collectively, our studies suggest that anti-CCR4 mAb could be an ideal treatment modality for patients with CCR4-positive HL not only to overcome the suppressive effect of CCR4 þ Treg cells on the host's immune response to HL cells but also to directly kill the HL cells. On the other hand, it should be noted that anti-CCR4 mAb might result in induction of autoimmunity, as reported in the anti-CTLA-4 mAb study. 30 With this in mind, before clinical use, anti-CCR4 mAb underwent extensive evaluation in cynomolgus monkeys. Because the binding affinity of this mAb to monkey and human CCR4 was almost identical, we believe that the former are suitable for evaluating safety in humans. The anti-CCR4 mAb was found not to cause any notable acute or chronic clinical toxicity in cynomolgus monkeys (unpublished data from Kyowa Hakko Kogyo Inc.). Eventually, combination treatment with this mAb and conventional chemotherapy may be as successful in HL patients as combination treatment with other antibodies, such as trastuzumab, 4 rituximab, 5 bevacizumab 6 and cetuximab, 7 has been in other types of cancer.
